The global viral vector manufacturing market is anticipated to expand at substantial CAGR of 20.0% during the forecast period, between 2021 and 2028.
Vaccination which is used to deliver genetic coding of a specific antigen into the recipient's host cells by using viral vector is known as viral vector vaccine. In this, the strain of modified virus version which is not the virus is being targeted to transfer relevant information to the human cells. Vector virus is the virus in which there are some changes made in such a way that the human cells are able to form antibodies accordingly before the action of actual virus strain. Antigens, which are innocuous components of the virus that provoke an immune response in the body, are then produced by the cells.
Market Trends, Drivers, Restraints, and Opportunities:
- Increasing demand for viral vector manufacturing from the pharmaceutical industry for various research purposes is fueling the market.
- Rising prevalence of target diseases and disorders is expected to drive the demand for viral vector manufacturing in the coming years.
- Continuous innovation is increasing costs, which in turn is expected to hamper the market growth.
- Growing investment for gene therapy development is anticipated to provide lucrative opportunities for market players during the forecast period.
Scope of the report:
The report on viral vector manufacturing market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
Attributes
|
Details
|
Report Title
|
Viral Vector Manufacturing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
Base Year
|
2020
|
Historic Data
|
2018–2019
|
Forecast Period
|
2021–2028
|
Segmentation
|
Types (Adenoviral Vectors, Retroviral Vectors, Adeno-associated Viral Vectors, and Others), Diseases (Infectious Diseases, Cancer, Genetic Disorders, and Others), Applications (Gene Therapy and Vaccinology), End-users (Research Institutes, Pharmaceutical & Biopharmaceutical Companies, and Others)
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
Key Players Covered in the Report
|
Lonza, Merck KGaA, Oxford Biomedica, CGT Catapult, Charles River Laboratories., uniQure N.V., F. Hoffmann-La Roche Ltd (Spark Therapeutics), FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Kaneka Eurogentec S.A., Janssen Pharmaceutica NV, AstraZeneca, Vibalogics, Sanofi, Thermo Fisher Scientific Inc. and Danaher (Cytiva)
|
Viral Vector Manufacturing Market Segment Insights:
The adeno-associated viral vector segment is projected to hold significant market share
In terms of types, the viral vector manufacturing market can be segregated into adenoviral vectors, retroviral vectors, adeno-associated viral vectors, and others. The adeno-associated viral vector segment is anticipated to expand at a high CAGR during the forecast period as they are used in the majority of cell-based gene treatments.
The cancer segment held substantial market share in 2020
Based on diseases, the viral vector manufacturing market can be fragmented into infectious diseases, cancers, genetic disorders, and others. The cancer segment is estimated to hold majority of the global market share during the forecast period. The expanding study on viral vector gene treatments for cancer can be attributed to its significant rise.
The gene therapy segment held substantial market share in 2020
Based on applications, the viral vector manufacturing market can be bifurcated into gene therapy and vaccinology. The gene therapy segment is expected to increase at the rapid pace during the projected period. Growth of the market is attributed to availability of effective viral vector gene therapies for rare diseases and cancers, ongoing research on viral vector gene therapies, and recent approval of various viral vector gene treatments.
The pharmaceutical & biotechnology industries segment to grow during the forecast period
On the basis of end-users, the market can be segregated research institutes, pharmaceutical & biopharmaceutical companies, and others. The pharmaceutical & biopharmaceutical companies’ segment is anticipated to hold majority of the worldwide industry during the forecast period. The successful launch of viral vector gene treatments, as well as a healthy pipeline of such therapies, are significant drivers of the pharmaceutical & biopharmaceutical companies' segment.
Asia Pacific dominates the global market
In terms of regions, the global viral vector manufacturing market can be split into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific accounted for a considerable share of the market in 2020 due to leading market players' mergers and acquisitions. The rapid expansion of this geographical segment can be attributed to ongoing research initiatives aimed at launching novel gene therapies in the region's untapped markets.
Segments
Types
- Adenoviral Vectors
- Retroviral Vectors
- Adeno-associated Viral Vectors
- Others
Diseases
- Infectious diseases
- Cancers
- Genetic Disorders
- Others
Applications
End-users
- Research Institutes
- Pharmaceutical & Biopharmaceutical Companies
- Others
Regions
- North America
- Europe
- Latin America
- Asia Pacific
- Middle East & Africa
Key Players
- Lonza
- Merck KGaA
- Oxford Biomedica
- CGT Catapult
- Charles River Laboratories
- uniQure N.V.
- F. Hoffmann-La Roche Ltd (Spark Therapeutics)
- FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
- Kaneka Eurogentec S.A.
- Janssen Pharmaceutica NV
- AstraZeneca
- Vibalogics
- Sanofi
- Thermo Fisher Scientific Inc.
- Danaher (Cytiva)
Competitive Landscape
Key players in the viral vector manufacturing market include Lonza, Merck KGaA, Oxford Biomedica, CGT Catapult, Charles River Laboratories., uniQure N.V., F. Hoffmann-La Roche Ltd (Spark Therapeutics), FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Kaneka Eurogentec S.A., Janssen Pharmaceutica NV, AstraZeneca, Vibalogics, Sanofi, Thermo Fisher Scientific Inc. and Danaher (Cytiva). These players engage in mergers & acquisitions, collaborations, agreements, and partnerships to strengthen their geographical presence.